RU94002475A - Фармацевтическая композиция и ее применение для лечения вирусных инфекций - Google Patents

Фармацевтическая композиция и ее применение для лечения вирусных инфекций

Info

Publication number
RU94002475A
RU94002475A RU94002475/14A RU94002475A RU94002475A RU 94002475 A RU94002475 A RU 94002475A RU 94002475/14 A RU94002475/14 A RU 94002475/14A RU 94002475 A RU94002475 A RU 94002475A RU 94002475 A RU94002475 A RU 94002475A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
viral infection
infection treatment
treatment
ribofuranosyl
Prior art date
Application number
RU94002475/14A
Other languages
English (en)
Inventor
Маргарет Тисдейл Сильвия
Gb]
Ван Таттл Джоэл
Джон Слейтер Мартин
Us]
Мери Делудж Сусан
Говард Миллер Вейн
Энтони Кренитски Томас
Уолтер Кожалка Джордж
Original Assignee
Дзе Веллкам Фаундейшн Лимитед (GB)
Дзе Веллкам Фаундейшн Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Веллкам Фаундейшн Лимитед (GB), Дзе Веллкам Фаундейшн Лимитед filed Critical Дзе Веллкам Фаундейшн Лимитед (GB)
Publication of RU94002475A publication Critical patent/RU94002475A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Local Oxidation Of Silicon (AREA)
  • Element Separation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Изобретение относится к фармацевтическим композициям, содержащим 9-(2-дезокси-2-фтор-бета-D-рибофуранозил)гуанин, его физиологически приемлемые соли и сложные эфиры, и их применению в медицинской практике, в частности для лечения инфекционных заболеваний, в том числе инфекций, вызванных вирусом гриппа и респираторно-синцитиальным вирусом.

Claims (1)

  1. Изобретение относится к фармацевтическим композициям, содержащим 9-(2-дезокси-2-фтор-бета-D-рибофуранозил)гуанин, его физиологически приемлемые соли и сложные эфиры, и их применению в медицинской практике, в частности для лечения инфекционных заболеваний, в том числе инфекций, вызванных вирусом гриппа и респираторно-синцитиальным вирусом.
RU94002475/14A 1989-09-11 1994-01-14 Фармацевтическая композиция и ее применение для лечения вирусных инфекций RU94002475A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8920534-8 1989-09-11
GB898920534A GB8920534D0 (en) 1989-09-11 1989-09-11 Antiviral compounds

Publications (1)

Publication Number Publication Date
RU94002475A true RU94002475A (ru) 1996-11-10

Family

ID=10662891

Family Applications (2)

Application Number Title Priority Date Filing Date
SU904831211A RU2043361C1 (ru) 1989-09-11 1990-09-10 Способ получения производных 2'-дезокси-2'-фторрибонуклеозидов или их фармацевтически приемлемых солей
RU94002475/14A RU94002475A (ru) 1989-09-11 1994-01-14 Фармацевтическая композиция и ее применение для лечения вирусных инфекций

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SU904831211A RU2043361C1 (ru) 1989-09-11 1990-09-10 Способ получения производных 2'-дезокси-2'-фторрибонуклеозидов или их фармацевтически приемлемых солей

Country Status (19)

Country Link
EP (2) EP0417999B1 (ru)
JP (1) JPH03145497A (ru)
KR (1) KR910006293A (ru)
AT (1) ATE135365T1 (ru)
AU (1) AU644095B2 (ru)
CA (1) CA2025009A1 (ru)
DD (1) DD297650A5 (ru)
DE (1) DE69025834D1 (ru)
FI (1) FI904445A0 (ru)
GB (1) GB8920534D0 (ru)
HU (1) HUT54704A (ru)
IE (1) IE903269A1 (ru)
MY (1) MY130035A (ru)
NZ (1) NZ235244A (ru)
PL (1) PL164967B1 (ru)
PT (1) PT95261A (ru)
RU (2) RU2043361C1 (ru)
TW (2) TW246641B (ru)
ZA (1) ZA907187B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95384C (fi) * 1989-04-06 1996-01-25 Squibb Bristol Myers Co Menetelmä 3'-deoksi-3'-substituoitujen metyylinukleosidien valmistamiseksi ja menetelmässä käytettäviä välituotteita
US5914396A (en) * 1990-01-11 1999-06-22 Isis Pharmaceuticals, Inc. 2'-O-modified nucleosides and phosphoramidites
US5872232A (en) * 1990-01-11 1999-02-16 Isis Pharmaceuticals Inc. 2'-O-modified oligonucleotides
US5670633A (en) * 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US6399754B1 (en) 1991-12-24 2002-06-04 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides
US5859221A (en) * 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
AU7558491A (en) * 1990-04-04 1991-10-30 Nycomed Imaging As Nucleoside derivatives
US5623070A (en) * 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5677437A (en) * 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5792844A (en) * 1990-07-27 1998-08-11 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent nitrogen atoms
US5618704A (en) * 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
AU1254892A (en) * 1990-12-18 1992-07-22 Sloan-Kettering Institute For Cancer Research Novel synthesis of 2'-"up" fluorinated 2''-deoxy-arabinofuranosylpurines
US5672697A (en) * 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5965722A (en) 1991-05-21 1999-10-12 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
US6307040B1 (en) 1992-03-05 2001-10-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US7119184B2 (en) 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US5393841A (en) * 1993-11-09 1995-02-28 Shell Oil Company Dissimilar arm asymmetric radial or star block copolymers for adhesives and sealants
US6413410B1 (en) 1996-06-19 2002-07-02 Lifescan, Inc. Electrochemical cell
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
EP0917879B1 (de) * 1997-11-22 2002-07-17 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Stabilisierung von Proteinen
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
DK1058686T3 (da) * 1998-02-25 2007-03-05 Univ Emory 2'-fluornukleosider
EP1411954B1 (en) 2000-10-18 2010-12-15 Pharmasset, Inc. Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
US7132453B2 (en) * 2002-03-15 2006-11-07 Vanderbilt University Method of using prostacyclin to treat respiratory syncytial virus infections
AU2003290596B2 (en) 2002-11-05 2011-05-12 Isis Pharmaceuticals, Inc. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
WO2008109080A2 (en) * 2007-03-01 2008-09-12 Siemens Medical Solutions Usa, Inc. Nucleoside based proliferation imaging markers
US8975389B2 (en) 2009-03-02 2015-03-10 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
EP2937420A1 (en) * 2014-04-23 2015-10-28 Synbias Pharma AG Method for the synthesis of clofarabine
JP6983814B2 (ja) * 2016-12-14 2021-12-17 ヤマサ醤油株式会社 抗ウイルス活性を示すヌクレオシド誘導体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
CA1340645C (en) * 1987-04-17 1999-07-13 Victor E. Marquez Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus

Also Published As

Publication number Publication date
EP0417999A1 (en) 1991-03-20
DE69025834D1 (de) 1996-04-18
NZ235244A (en) 1992-11-25
EP0417999B1 (en) 1996-03-13
MY130035A (en) 2007-05-31
KR910006293A (ko) 1991-04-29
ZA907187B (en) 1992-05-27
PL164967B1 (pl) 1994-10-31
AU6235090A (en) 1991-03-14
TW226333B (ru) 1994-07-11
RU2043361C1 (ru) 1995-09-10
AU644095B2 (en) 1993-12-02
HUT54704A (en) 1991-03-28
FI904445A0 (fi) 1990-09-10
PT95261A (pt) 1991-05-22
EP0671410A1 (en) 1995-09-13
DD297650A5 (de) 1992-01-16
CA2025009A1 (en) 1991-03-12
ATE135365T1 (de) 1996-03-15
JPH03145497A (ja) 1991-06-20
GB8920534D0 (en) 1989-10-25
TW246641B (ru) 1995-05-01
PL286820A1 (en) 1991-04-22
IE903269A1 (en) 1991-03-27

Similar Documents

Publication Publication Date Title
RU94002475A (ru) Фармацевтическая композиция и ее применение для лечения вирусных инфекций
MY117892A (en) Therapeutic compounds
BG86132A (bg) Производни на пиридазинамин
MY107843A (en) Anti-viral compounds.
CA2293470A1 (en) Benzimidazole derivatives
RU94028670A (ru) Иммунопотенциирующие агенты, способы лечения иммунодефицитных млекопитающих, а также вирусных инфекций и рака у млекопитающих
ATE87484T1 (de) Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
PT92949A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados da cisteina para o tratamento de doencas associadas com infeccoes provocadas por virus da imunodeficiencia humano
DK166715B1 (da) Farmaceutiske produkt og anvendelse af dette til fremstilling af et kombinationspraeparat til behandling af virusinfektioner
MX9805441A (es) Compuestos terapeuticos.
BR9508629A (pt) Composto solvato e hidrato do mesmo processos para o tratamento ou profilaxia de uma infecção viral num ser humano e para a preparação do composto uso de um composto e formulação farmacêutica
CO4520283A1 (es) Agentes antivirales
SK129999A3 (en) Pharmaceutical composition, preparation process and use thereof
MX9301922A (es) Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv).
FR2694693B1 (fr) Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
EA200400691A1 (ru) Получение чистых стереоизомеров трицикло[5,2,1,02,6]дец-9-ил-ксантогената и содержащие их лекарственные средства
RU94045140A (ru) Фармацевтическая композиция для профилактики или лечения вирусных заболеваний, способ ее получения и применение антагониста брадикинина или его физиологически переносимой соли в качестве средства для профилактики или лечения вирусных заболеваний
RU2002107675A (ru) Лекарственные средства с содержанием ксеногенных олиго- или/и полирибонуклеотидов
Clyde et al. Therapeutic trials of chloroquine silicate in Tanganyika
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
RU94016333A (ru) Лекарственное средство для лечения вирусных заболеваний
TH16738A (th) " อนุพันธ์ยูรีโดที่ออกฤทธิ์ทางชีวภาพที่มีประโยชน์ในการบำบัดโรคที่เกิดจากเล็นทิไวรัส "
BR9809124A (pt) Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente
RU93048568A (ru) 14,14,14-трифтор-12-оксатетрадекановая кислота, липидный ингибитор вируса иммунодефицита человека
UA58059A (ru) Способ профилактики гриппа